Although there have been significant advances in understanding the clinical and biochemical features of primary biliary cirrhosis (PBC), there is still a paucity of data on the usefulness of biomarkers as prognostic indicators. This is particularly important at the time of initial diagnosis. Indeed,
Practice variation in treatment of primary biliary cirrhosis and effect on clinical outcomes
โ Scribed by Jayant A. Talwalkar; Andrea A. Gossard
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 42 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
The article by Jackson et al. 1 and accompanying editorial by Corpechot and Poupon 2 have raised the interesting question of practice variation in the diagnosis and treatment of primary biliary cirrhosis (PBC). In general, the variable use of effective medical therapies continues to be linked with the notion of inconsistent clinical outcomes for chronic disease overall. 3 Given the available data, it is difficult to ignore the likelihood that ursodeoxycholic acid (UDCA) therapy has influenced the natural history of PBC in various populations. In addition, there is empiric evidence supporting the existence of practice variation in UDCA prescribing patterns for PBC within the United States. 4 Specifically, the timing of UDCA therapy may be quite varied with at least 10% of patients beginning UDCA greater than 1 year after initial diagnosis.
Although specific details about provider adherence rates to weightbased dosing (13-15 mg/kg/day) remain unavailable, it is likely that significant variations exist in the United States, given the large dose range (from 1.5 to 23.1 mg/kg/day, median 11.5) reported by practicing gastroenterologists in the United Kingdom. 5 Drug-related adverse event rates as high as 35% leading to UDCA discontinuation are also reported among U.S. residents with PBC. 4 This far exceeds rates observed in published randomized controlled trials to date. Given the cohort used by Jackson et al., it would have been intriguing to know how often dose reduction and/or drug cessation occurred in their population. Finally, medical therapies with questionable or no benefit for PBC are prescribed by 10%-15% of providers based on published reports. 5 Estimated rates of similar practices in the United States remain unknown.
Despite the overall rarity of PBC, these observations underscore the need to recognize differences in treatment patterns which may influence long-term outcome in PBC. Similarly, ongoing educational efforts to decrease the use of ineffective therapies with unfavorable risk/ benefit profiles in altering the natural history of PBC would be welcomed.
๐ SIMILAR VOLUMES
In this study we have determined the incidence of hepatocellular carcinoma (HCC) development in primary biliary cirrhosis (PBC) and its effects on patient survival. Six hundred and sixty seven patients with liver histology compatible with or diagnostic of PBC were seen over a 20-year period. Two hun
Primary biliary cirrhosis (PBC) is sometimes diagnosed based on a positive antimitochondrial antibody in the appropriate clinical setting without a liver biopsy. Although a liver biopsy can assess the extent of liver fibrosis and provide prognostic information, serum fibrosis markers avoid biopsy co
Quality of life is an important concern for patients with chronic liver disease. We sought to describe the frequency, severity, and associations of fatigue, in patients with primary biliary cirrhosis (PBC). We performed association testing between PBC-40 multidomain disease-specific quality of life
Bile acid composition in fasting duodenal bile was assessed at entry and at 2 years in patients with primary biliary cirrhosis (PBC) enrolled in a randomized, doubleblind, placebo-controlled trial of ursodeoxycholic acid (UDCA) (10-12 mg/kg/d) taken as a single bedtime dose. Specimens were analyzed